Skip to content
Disclosery

GILEAD SCIENCES, INC.

Follow

13F filer, CIK 882095, FOSTER CITY, CA

GILEAD SCIENCES, INC. reported $1,181,331,731 across 14 holdings for the quarter ended 2025-03-31, in a 13F-HR filed 2025-05-13. Its ten largest share positions make up 99.56% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-25-000217

Period
2025-03-31
Reported value
$1.18B
Holdings
14
Top 10 weight
99.56%
New
1
Sold out
3

Part of the filer group GILEAD SCIENCES, INC.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RCUSadded+1,363,636$10.7M
KLRSnew+723,273$5.81M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ALLOVIR INCexited-16,635,286-$6.99M
IKENA ONCOLOGY INCreduced-849,193-$1.09M
AGENexited-231,663-$635K
BRNSreduced-250,496-$244K
KRONOS BIO INCexited-188,567-$179K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2025

Share positions as resolved from 13F-HR 0001123292-25-000217, largest first. % of portfolio is the value over $1,181,331,731, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,720,803 shares; 2025Q1: 6,720,803 shares 6,720,803$441M37.32%0Timeline
LKFTLAKEFRONT BIOTHERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 16,707,477 shares; 2025Q1: 16,707,477 shares 16,707,477$419M35.5%0Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 30,061,124 shares; 2025Q1: 31,424,760 shares 31,424,760$247M20.88%+1,363,636Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,209,471 shares; 2025Q1: 2,209,471 shares 2,209,471$21.1M1.79%0Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 452,527 shares; 2025Q1: 452,527 shares 452,527$19M1.61%0
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,126,119 shares; 2025Q1: 4,126,119 shares 4,126,119$7.96M0.67%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 4,854,443 shares; 2025Q1: 4,854,443 shares 4,854,443$6.65M0.56%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 9,105,451 shares; 2025Q1: 9,105,451 shares 9,105,451$6.6M0.56%0Timeline
KLRSKALARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 723,273 shares 723,273$5.81M0.49%newTimeline
HOOKHOOKIPA PHARMA INC COM NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,875,945 shares; 2025Q1: 1,875,945 shares 1,875,945$2.03M0.17%0Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,156,689 shares; 2025Q1: 1,156,689 shares 1,156,689$1.69M0.14%0Timeline
CYPHCYPHERPUNK TECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 5,319,148 shares; 2025Q1: 5,319,148 shares 5,319,148$1.62M0.14%0Timeline
IKENA ONCOLOGY INCIKENA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,008,338 shares; 2025Q1: 1,159,145 shares 1,159,145$1.48M0.13%-849,193
BRNSBARINTHUS BIOTHERAPEUTICS PLQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 620,351 shares; 2025Q1: 369,855 shares 369,855$360K0.03%-250,496Timeline

Sold out in Q1 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ALLOVIR INCALLOVIR INC16,635,286$6.99Mshares
AGENAGENUS INC231,663$635Kshares
KRONOS BIO INCKRONOS BIO INC188,567$179Kshares

How Q1 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-25-000217 base2025-05-13acceptance time not in the bulk data set